novo-nordisk-vergleich-mit-hims-&-hers - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,839 +0.83%

DJIA 48,339 +0.90%

Nasdaq 25,091 +0.79%

DAX 23,928 -0.15%

Gold $4,196 +0.16%

Oil $95.75 -0.97%

BTC $72,426 +1.48%

VIX 20.43 -15.85%

EUR/USD 1.1785 -0.02%

ETH $2,222 +0.59%

S&P 500 6,839 +0.83%

DJIA 48,339 +0.90%

Nasdaq 25,091 +0.79%

DAX 23,928 -0.15%

Gold $4,196 +0.16%

Oil $95.75 -0.97%

BTC $72,426 +1.48%

VIX 20.43 -15.85%

EUR/USD 1.1785 -0.02%

ETH $2,222 +0.59%

novo-nordisk—vergleich-mit-hims-&-hers

Novo Nordisk Hims partnership GLP-1 drugs Wegovy and Ozempic showcased as premium treatment options

Pharma & Healthcare·Stocks·Europe

Novo Nordisk Hims partnership Boom: GLP‑1 market power shift

By Maik Kemper • Mar 9, 2026

Novo Nordisk Hims partnership GLP-1 drugs Wegovy and Ozempic showcased as premium treatment options

Pharma & Healthcare·Stocks·Europe

Novo Nordisk Hims partnership Boom: GLP‑1 market power shift

By Maik Kemper • Mar 9, 2026

Can the Novo Nordisk Hims partnership turn a legal fight over compounded GLP‑1s into a powerful new growth channel for both sides? How does the…